The pharmaceutical industry continues to be a hotbed of innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Genomics in pharmaceuticals: T-Cell culturing. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
T-cell culturing is a key innovation area in genomics
Optimized culture conditions for T-cell expansion are elusive, as many different factors contribute to the eventual outcome. T-cell stimulation and co-stimulation methods, different cytokines, growth media and serum, oxygen concentration, ambient pH, initial seeding density, and a static or dynamic culture are all factors that influence the outcome of T-cell expansion. To generate polyclonal T-cells, resting T-cells must first be activated with primary and secondary signals from CD3 and CD28 stimulation, respectively. Activation of T-cells can be achieved using an anti-CD3 antibody (OKT3) and irradiated feeder cells. However, a more accessible strategy for activating T-cells is by adding small magnetic beads coated with anti-CD3/CD28 antibodies. Proliferation of T-cells requires growth factors supplied by the medium and serum. One of the growth factors is interleukin-2 (IL-2), which by binding to its receptor, promotes polyclonal proliferation of T-cells by binding to its cell surface receptor.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 420+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of T-cell culturing.
Key players in T-cell culturing – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to T-cell culturing
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Immatics||848||Unlock company profile|
|Johnson & Johnson||567||Unlock company profile|
|Bristol-Myers Squibb||405||Unlock company profile|
|Iovance Biotherapeutics||383||Unlock company profile|
|Cellectis||213||Unlock company profile|
|Fujifilm||211||Unlock company profile|
|OncoTherapy Science||205||Unlock company profile|
|ViaCyte||166||Unlock company profile|
|Fate Therapeutics||164||Unlock company profile|
|Immunovative Therapies||150||Unlock company profile|
|Astellas Pharma||142||Unlock company profile|
|Fred Hutchinson Cancer Research Center||110||Unlock company profile|
|Takeda Pharmaceutical||104||Unlock company profile|
|Gilead Sciences||91||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||90||Unlock company profile|
|Lonza Group||84||Unlock company profile|
|BioNTech||76||Unlock company profile|
|Sangamo Therapeutics||70||Unlock company profile|
|Ministry of Trade and Industry, Singapore||69||Unlock company profile|
|Allele Biotechnology and Pharmaceuticals||57||Unlock company profile|
|Children's Medical Center||54||Unlock company profile|
|East-West Capital Partners||54||Unlock company profile|
|Children’s National Health System||52||Unlock company profile|
|Miltenyi Biotec||52||Unlock company profile|
|I'rom Group||51||Unlock company profile|
|CRISPR Therapeutics||49||Unlock company profile|
|Gamida Cell||46||Unlock company profile|
|Seattle Children's Hospital||46||Unlock company profile|
|Takara||45||Unlock company profile|
|PolyBioCept||45||Unlock company profile|
|Thermo Fisher Scientific||44||Unlock company profile|
|Genesis Technologies||42||Unlock company profile|
|WindMIL Therapeutics||42||Unlock company profile|
|Mesoblast||41||Unlock company profile|
|Geneius Biotechnology||40||Unlock company profile|
|Adicet Bio||39||Unlock company profile|
|Taiga Biotechnologies||39||Unlock company profile|
|bluebird bio||39||Unlock company profile|
|Centre National de la Recherche Scientifique||38||Unlock company profile|
|Assistance Publique - Hopitaux de Paris||38||Unlock company profile|
|Editas Medicine||37||Unlock company profile|
|Athenex||36||Unlock company profile|
|Novartis||36||Unlock company profile|
|Cedars-Sinai Health System||35||Unlock company profile|
|Cellscript||35||Unlock company profile|
|F. Hoffmann-La Roche||35||Unlock company profile|
|GI Cell||33||Unlock company profile|
|Poseida Therapeutics||33||Unlock company profile|
|BioLamina||33||Unlock company profile|
|NEW HOPE, CITY OF||33||Unlock company profile|
Source: GlobalData Patent Analytics
Immatics is the leading patent filer in T-cell culturing. Immatics is a biopharmaceutical company focused on the development of T-cell immunotherapies to treat cancer. Immatics is headquartered in Tuebingen, Germany. Johnson & Johnson and Bristol-Myers Squibb are the other key patent filers in T-cell culturing.
In terms of application diversity, Immatics is the top company, followed by Seattle Children's Hospital and Immunovative Therapies. By means of geographic reach, BioLamina holds the top position. Whilst Immatics and East-West Capital Partners stand in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.